Form 4: Brainstorm Cell Therapeutics CEO Lebovits Increases Stake in Company
SEC Form 4 Filing
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired additional shares of the company's common stock through a series of transactions.
Summary
- Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics Inc., has increased his holdings in the company.
- On May 10, 2024, he acquired 20,000 shares of common stock at a price of $0.465 per share.
- He further acquired 10,000 shares on May 11, 2024, at $0.4665 per share, and another 10,000 shares on May 13, 2024, at $0.49 per share.
- Following these transactions, Lebovits directly owns 1,099,865 shares of Brainstorm Cell Therapeutics Inc.
- He may also be deemed the beneficial owner of 2,000,847 shares held by ACCBT Corp. and ACC International Holdings Ltd.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which signals confidence. However, it's a routine filing, so the impact is limited.
Positives
- The CEO's increased investment could be interpreted as a positive signal about his confidence in the company's future prospects.
Industry Context
Insider buying is often viewed as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Key Dates
| Date | Description |
|---|---|
| 05/10/2024 | Acquisition of 20,000 shares at $0.465 per share. |
| 05/11/2024 | Acquisition of 10,000 shares at $0.4665 per share. |
| 05/13/2024 | Acquisition of 10,000 shares at $0.49 per share. |
| 05/14/2024 | Date of signature for the SEC Form 4 filing. |
Keywords
Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock Acquisition, SEC Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.